Baseline characteristics of study patients (intent-to-treat population)
| ETN (n = 159) | ETN+MTX (n = 155) | |
|---|---|---|
| DAS28, Disease Activity Score-28 joint count; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; ETN, etanercept; HAQ, Health Assessment Questionnaire; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis; VAS, Visual Analogue Scale. | ||
| Mean age, years | 53 | 54 |
| Ethnic origin, n (%) | ||
| White | 158 (99.4) | 153 (98.7) |
| Black | 0 (0) | 2 (1.3) |
| Asian | 1 (0.6) | 0 (0) |
| Sex, n (%) | ||
| Female | 126 (79.2) | 119 (76.8) |
| Male | 33 (20.8) | 36 (23.2) |
| Mean time since primary diagnosis,years | 10.0 | 9.8 |
| Rheumatoid factor positive, % | 70.9 | 69.5 |
| Prior corticosteroid use, n (%) | 78 (49.1) | 86 (55.5) |
| Prior NSAID use, n (%) | 116 (73) | 123 (79.4) |
| Mean ESR, mm/h | 33.2 | 36.7 |
| Mean duration of morning stiffness,min | 235 | 261 |
| Mean DAS28 (4) | 6.2 | 6.3 |
| Median MTX dose, mg/week | 15 | 15 |
| Mean no of prior DMARDs | 2.2 | 2.3 |
| Mean no of total joint replacements | 15.7 | 16.8 |
| Mean general health VAS (0–100) | 62.3 | 59.4 |
| Mean pain VAS (0–100) | 62.7 | 63.3 |
| Global assessment of RA activity VAS (0–10) | 6.6 | 6.6 |
| Mean HAQ (0–3) | 1.6 | 1.7 |
| Mean no of swollen joints | 11.2 | 11.9 |
| Mean no of tender joints | 14.6 | 14.7 |